Posaconazole

Generic Name
Posaconazole
Brand Names
Noxafil, Posanol, Posaconazole Accord, Posaconazole AHCL
Drug Type
Small Molecule
Chemical Formula
C37H42F2N8O4
CAS Number
171228-49-2
Unique Ingredient Identifier
6TK1G07BHZ
Background

Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients.

Indication

For prophylaxis of invasive Aspergillus and Candida infections in patients, 13 years of age and older, who are at high risk of developing these infections due to being severely immunocompromised as a result of procedures such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD), or due to hematologic malignancies with...

Associated Conditions
Candidiasis, Coccidioidomycosis, Esophageal Candidiasis, Fungal Infections, Invasive Aspergillosis, Invasive bronchopulmonary aspergillosis, Mucormycosis, Oropharyngeal Candidiasis, Prophylaxis of Aspergillus infection, Pulmonary cryptococcosis infection
Associated Therapies
-
Clinical Trials
Related News

POS vs FLU for First Line Treatment of Coccidioidomycosis (Study P04558Am1)(COMPLETED)

Phase 3
Completed
Conditions
Coccidioidomycosis
Interventions
Drug: Fluconazole
Drug: Posaconazole
First Posted Date
2007-01-18
Last Posted Date
2017-04-11
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
16
Registration Number
NCT00423267

Limited Access Protocol of Posaconazole in Invasive Fungal Infections Study PO2095

Phase 4
Terminated
Conditions
Fungal Infection
First Posted Date
2005-09-15
Last Posted Date
2008-12-17
Lead Sponsor
University of Pittsburgh
Target Recruit Count
10
Registration Number
NCT00177749
Locations
🇺🇸

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

Open Label Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P00041)

Phase 3
Completed
Conditions
Mycoses
First Posted Date
2002-05-02
Last Posted Date
2017-03-10
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
336
Registration Number
NCT00034658

Posaconazole to Treat Invasive Fungal Infections

First Posted Date
2002-04-19
Last Posted Date
2017-07-02
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
50
Registration Number
NCT00033982
Locations
🇺🇸

Schering-Plough Research Institute, Kenilworth, New Jersey, United States

Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients

Phase 3
Completed
Conditions
Candidiasis, Oral
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Schering-Plough
Target Recruit Count
300
Registration Number
NCT00002446
Locations
🇺🇸

ViRx Inc, San Francisco, California, United States

🇺🇸

Boulevard Comprehensive Care Ctr, Jacksonville, Florida, United States

🇺🇸

Miami Veterans Administration Med Ctr, Miami, Florida, United States

and more 15 locations

A Comparison of SCH 56592 and Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients

Phase 2
Completed
Conditions
Candidiasis, Oral
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Schering-Plough
Target Recruit Count
500
Registration Number
NCT00002399
Locations
🇺🇸

Wayne State Univ / Harper Hosp, Detroit, Michigan, United States

🇦🇷

Centro de Micologia / Facultad de Medicina UBA, Buenos Aires, Argentina

🇪🇹

Faculty of Medicine / Dept of Internal Medicine, Addis Ababa, Ethiopia

and more 49 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy